A Phase 1b clinical trial of PAC-1 for glioblastoma patients has begun

PAC-1

A drug that spurs cancer cells to self-destruct has been cleared for use in a clinical trial of patients with anaplastic astrocytoma, a rare malignant brain tumor, and glioblastoma multiforme, an aggressive late-stage cancer of the brain. This phase Ib trial will determine if the experimental drug PAC-1 can be used safely in combination with a standard brain-cancer chemotherapy drug, temozolomide.

Read the rest of the Illinois News Bureau story here.

Watch the WCIA news story here.